In the last trading session, 0.54 million shares of the Acrivon Therapeutics Inc (NASDAQ:ACRV) were traded, and its beta was 1.90. Most recently the company’s share price was $1.42, and it changed around $0.01 or 0.71% from the last close, which brings the market valuation of the company to $44.52M. ACRV currently trades at a discount to its 52-week high of $10.29, offering almost -624.65% off that amount. The share price’s 52-week low was $1.30, which indicates that the current value has risen by an impressive 8.45% since then.
Acrivon Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 9 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 0 recommended ACRV as a Hold, whereas 6 deemed it a Buy, and 0 rated it as Underweight. Acrivon Therapeutics Inc is expected to report earnings per share of -0.65 for the current quarter.
Acrivon Therapeutics Inc (NASDAQ:ACRV) trade information
Instantly ACRV has showed a green trend with a performance of 0.71% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 1.5500 on recent trading dayincreased the stock’s daily price by 8.39%. The company’s shares are currently down -76.41% year-to-date, but still down -8.39% over the last five days. On the other hand, Acrivon Therapeutics Inc (NASDAQ:ACRV) is -13.41% down in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $27, which translates to bulls needing to increase their stock price by 94.74% from its current value. Analyst projections state that ACRV is forecast to be at a low of $27 and a high of $27.
Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -74.96%. Acrivon Therapeutics Inc earnings are expected to increase by -8.08% in 2025, but the outlook is positive 0.28% per year for the next five years.
ACRV Dividends
Acrivon Therapeutics Inc’s next quarterly earnings report is expected to be released in June.
PERCEPTIVE ADVISORS LLC, with 14.8366% or 5.36 million shares worth $31.09 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF were the top two Mutual Funds as of Dec 31, 2024 . The former held 407.49 shares worth $0.58 million, making up 1.30% of all outstanding shares. On the other hand, iShares Trust-iShares Russell 2000 ETF held roughly 287.4 shares worth around $0.41 million, which represents about 0.92% of the total shares outstanding.
